448 related articles for article (PubMed ID: 23393200)
21. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
22. The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases.
Fafilek B; Balek L; Bosakova MK; Varecha M; Nita A; Gregor T; Gudernova I; Krenova J; Ghosh S; Piskacek M; Jonatova L; Cernohorsky NH; Zieba JT; Kostas M; Haugsten EM; Wesche J; Erneux C; Trantirek L; Krakow D; Krejci P
Sci Signal; 2018 Sep; 11(548):. PubMed ID: 30228226
[TBL] [Abstract][Full Text] [Related]
23. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
[TBL] [Abstract][Full Text] [Related]
24. CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen.
Lee S; Park H; Ha SY; Paik KY; Lee SE; Kim JM; Park JB; Kwon CH; Joh JW; Choi YL; Kim SJ
PLoS One; 2014; 9(8):e99452. PubMed ID: 25121597
[TBL] [Abstract][Full Text] [Related]
25. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
26. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
[TBL] [Abstract][Full Text] [Related]
27. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.
Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Gaither LA; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D
Cancer Discov; 2012 Dec; 2(12):1118-33. PubMed ID: 23002168
[TBL] [Abstract][Full Text] [Related]
28. p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics.
Kang Y; Horvai AE
Appl Immunohistochem Mol Morphol; 2017 Jan; 25(1):58-63. PubMed ID: 26509911
[TBL] [Abstract][Full Text] [Related]
29. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.
Coindre JM; Hostein I; Maire G; Derré J; Guillou L; Leroux A; Ghnassia JP; Collin F; Pedeutour F; Aurias A
J Pathol; 2004 Jul; 203(3):822-30. PubMed ID: 15221942
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
32. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways.
Hadari YR; Gotoh N; Kouhara H; Lax I; Schlessinger J
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8578-83. PubMed ID: 11447289
[TBL] [Abstract][Full Text] [Related]
33. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.
de Vreeze RS; de Jong D; Tielen IH; Ruijter HJ; Nederlof PM; Haas RL; van Coevorden F
Mod Pathol; 2009 Feb; 22(2):223-31. PubMed ID: 18820664
[TBL] [Abstract][Full Text] [Related]
34. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).
Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065
[TBL] [Abstract][Full Text] [Related]
35. EGFR and FGFR signaling through FRS2 is subject to negative feedback control by ERK1/2.
Wu Y; Chen Z; Ullrich A
Biol Chem; 2003 Aug; 384(8):1215-26. PubMed ID: 12974390
[TBL] [Abstract][Full Text] [Related]
36. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
37. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
38. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
[TBL] [Abstract][Full Text] [Related]
39. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
40. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
